



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_104_24

You asked:

I would be grateful if you could tell me how many patients were treated by individual drugs from the dermatology, gastroenterology, and rheumatology departments (for any disease) in 3 months from the start of October 2023 to the end of December 2023 (or the latest available 3 months).

I have provided a grid of drug names and department names requested in appendix A (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation (question 1).

Appendix A

Q1 – How many patients were treated with the following drugs from the following departments (for any disease) from the start of Oct 2023 to the end of Dec 2023?

Please use the latest available 3 months if October to December is not available and specify which 3 months has been used.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab (Humira)			
Adalimumab (Biosimilars)			
Apremilast			
Bimekizumab			
Brodalumab			
Certolizumab Pegol			
Deucravacitinib			
Etanercept (Enbrel)			
Etanercept (Biosimilars)			
Guselkumab			
Infliximab (Remicade)			
Infliximab (Biosimilars)			
Ixekizumab			
Risankizumab			
Secukinumab			
Tildrakizumab			
Ustekinumab			
Upadacitinib			
Vedolizumab			
Filgotinib			
Golimumab			
Mirikizumab			
Ozanimod			
Tofacitinib			
Abatacept			
Baricitinib			

Rituximab			
Sarilumab			
Tocilizumab			

Our response:

Please see below the table provided populated with the information Medicines Management are able to provide at this current time. The period the data relates to is 1st October 2023 to 31st December 2023.

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab (Humira)	**	6	82
Adalimumab (Biosimilars)	48	159	364
Apremilast	66		17
Bimekizumab	18		**
Brodalumab	**		
Certolizumab Pegol	6		59
Deucravacitinib			
Etanercept (Enbrel)			25
Etanercept (Biosimilars)			296
Guselkumab	35		**
Infliximab (Remicade)	0	**	**
Infliximab (Biosimilars)	**	211	22
Ixekizumab	19		21
Risankizumab	51	**	
Secukinumab	**		89
Tildrakizumab	14		
Ustekinumab	37	161	11
Upadacitinib	12	18	15

Vedolizumab		182	
Filgotinib		**	6
Golimumab		0	62
Mirikizumab			
Ozanimod			
Tofacitinib		**	10
Abatacept			55
Baricitinib	5		14
Rituximab			53
Sarilumab			**
Tocilizumab		**	90